About Nutriband Inc
- Industry: Pharmaceuticals
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://nutriband.com/
Frequently Asked Questions
What is the 52-week range for NTRB?
The 52-week high is $9.1851 and the 52-week low is $2.8.
What is the P/E ratio for NTRB?
The P/E ratio data is currently unavailable.
What is the dividend yield for NTRB?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -109.02%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -430.43%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 8.55.
Analyst Recommendation Trends
Wall Street analyst consensus for NTRB over the last few months:
Latest NTRB News
Nutriband Marks Five Years on Nasdaq – CEO Letter to Shareholders
Nutriband CEO Gareth Sheridan Congratulates Shareholders on Five-Year Nasdaq Listing Anniversary CEO letter reflects on five years of milestones since the Company's October 1, 2021 uplisting, as AVERSA™ Fentanyl advances toward an IND filing and the 2021 offering warrants expire as scheduled ORLANDO, Fla., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ: NTRB) today announced that CEO Gareth Sheridan has published a letter to shareholders marking the fifth anniversary of the Company's l
Nutriband CEO Gareth Sheridan Featured in New Nick Shirley Documentary Confronting America's Opioid Crisis
Sheridan joins independent journalist Nick Shirley to discuss how Nutriband's AVERSA™ abuse-deterrent technology is designed to help reduce the abuse, misuse, and accidental exposure driving the ongoing epidemicORLANDO, Fla., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) today announced that its CEO, Gareth Sheridan, has been featured in a new documentary by independent journalist and filmmaker Nick Shirley examining the ongoing opioid crisis in the United States.
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Kodiak Sciences (NASDAQ:KOD) shares increased by 57.4% to $50.93 during Monday's pre-market session. The market value of their outstanding shares is at $2.0 billion. Accuray (NASDAQ:ARAY) stock moved
Why Webuy Global Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
Webuy Global shares jumped 15% premarket after H1 revenue nearly doubled to $14.31M and net loss narrowed; Game Your Game led gainers, Masonglory fell.
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Firefly Neuroscience (NASDAQ:AIFF) shares increased by 33.2% to $1.58 during Friday's regular session. The company's market cap stands at $18.6 million. Apimeds Pharmaceuticals (AMEX:APUS) shares moved
Nutriband Appoints Decorated Navy SEAL and Veterans Health Advocate Robert J. O'Neill to Advisory Board
ORLANDO, Fla., Sept. 25, 2026 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) today announced the appointment of Robert J. O'Neill to its Advisory Board. O'Neill is a highly decorated former U.S. Navy SEAL, New York Times best-selling author, and nationally recognized speaker on leadership and resilience. O'Neill served 16 years in the U.S. Navy, including eight years with the Naval Special Warfare Development Group (SEAL Team Six), and took part in more than 400 combat missions
Nutriband Confirms Warrants Will Expire September 30 Without Extension or Repricing
ORLANDO, Fla., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) confirmed today that its outstanding warrants (NASDAQ:NTRBW) will expire on September 30, 2026 at 5PM ET as scheduled. The Company will not extend the expiration date and will not reprice the warrants. Warrant holders may exercise at the current strike price of $6.43 per share until the expiration date. Warrants not exercised by that date will expire in their entirety and be removed from the NTRBW Nasda
Nutriband CEO, Gareth Sheridan to Attend the Nasdaq Life Sciences Advisory Board (LaB) Biotech Summit
ORLANDO, Fla., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), today announced that its CEO, Gareth Sheridan will attend the inaugural Nasdaq LaB Biotech Summit on September 16th. The Summit brings together biotechnology executives, investors, and industry leaders for an evening of thought leadership and networking at Nasdaq MarketSite in New York. About AVERSA™ Abuse-Deterrent Transdermal Technology Nutriband's AVERSA™ abuse-deterrent transdermal technology incorp
Nutriband Receives USPTO Notice of Publication of Commercial Brand Name Trademarks for Its Abuse Deterrent Fentanyl Patch
Nutriband has received a Notice of Publication from the United States Patent and Trademark Office (USPTO) for commercial brand name trademarks for its lead product, an abuse deterrent fentanyl transdermal system. Once allowed, Nutriband plans to submit its commercial worldwide brand name to the FDA and other international regulatory agencies for approval. ORLANDO, Fla., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of prescrip
Nutriband Q2 EPS $(0.07) Up From $(2.12) YoY, Sales $437.514K Down From $622.452K YoY
Nutriband (NASDAQ:NTRB) reported quarterly losses of $(0.07) per share. This is a 96.7 percent increase over losses of $(2.12) per share from the same period last year. The company reported $437.514 thousand in sales